Green Engineering Solutions Ltd (GES Labs) has stated it intends to export into regions including Australia, Israel, EU, UK, South Africa, New Zealand, Canada and the US.
GES Labs is the first company in South Africa to receive the licence from the South Africa Health Products Regulatory Authority (SAHPRA).
The licence will allow the company to manufacture, import and export bulk active pharmaceutical ingredients (API) containing cannabinoids in accordance with the Medicines and Related Substances Act, 1965, and will last until 2026.
GES Labs, which is a licensed pharmaceutical manufacturer and exporter, has said that this will cover CBD Isolate APIs at 98+ per cent, CBD API at 90+ per cent CBD, THC API at 90+ per cent THC and USP generic Dronabinol.
GES Labs stated publicly: “GESLabs has rolled out our product offering for 2022.
“This quarter we will be focusing on our bulk cannabinoid product offering including CBD isolate, CBD intermediate, THC intermediate, and Dronabinol.
“In quarter one we will be focusing on delivering sample amounts for prospective clients while our global stability program is underway for Quarter 2 commercial supply.
“We will be looking to offer these products to Australia, Israel, EU, UK, South Africa, New Zealand, Canada, and US clients focussed on the pharmaceutical cannabinoid sector.”
On its website the company commented that: “The product certification ensures that all our cannabinoid APIs are of pharmaceutical quality suitable for medicine manufacturing.
“We use state-of-the-art manufacturing technologies to produce world-class extracts using high quality input materials from approved South African cultivators that have been approved through strictly controlled auditing programs.”
In December it said: “We have now been in production of cannabinoid APIs for a month and we will be finalizing our product validations with market-ready stability studies in the new year.”
[activecampaign form=31]
